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Abstract
Background:  Gastrointestinal stromal tumors are CD117 (C Kit) positive mesenchymal
neoplasms, that may arise anywhere in the gastrointestinal tract. Their current therapy is imatinib
mesylate before or after surgery.
Case presentation: We describe a case of 17-year-old female with metastasis to the cervix uteri
of a primary mesenteric gastrointestinal tumor.
Conclusion: Surgery remains the mainstay of known curative treatment. The manifestations of
GIST are not restricted to the typical locations within the bowel; may have very unusual metastatic
sites or infiltrations per continuitatem.
Background
Gastrointestinal stromal tumor (GIST) is a rare mesenchy-
mal tumor of the gastrointestinal tract with an incidence
of 10–20 cases per million populations of which almost
one third are deemed malignant [1]. We report this rare
case of primary mesenteric tumor metastatic to the cervix
that was diagnosed to be a GIST on histopathological
examination.
Case presentation
A 17 year old unmarried female presented with history of
menorrhagia and passing tissue per vagina since 3
months, low grade fever since 1 month and feeling of
mass per abdomen since 10 days. On examination, she
had a mass corresponding to 24 weeks size gravid uterus
arising from pelvis, which was tender on palpation. There
was anemia. Four units of blood transfusion were given in
a private clinic. Her routine liver and renal function tests
and coagulation profile were normal. Ultrasound fol-
lowed by contrast enhanced computerized tomography
(CT) showed bilateral adnexal masses with a large soft tis-
sue heterogeneous mass suggestive of sarcoma of the
uterus and presence of enlarged retroperitoneal lymph
nodes. Examination under anesthesia revealed the same
mass with side to side restricted mobility, and a fleshy, fri-
able and vascular growth protruding into vagina. Biopsy
from the growth was initially misdiagnosed as a leiomy-
osarcoma. Exploratory laparotomy was carried out as the
patient was continuously bleeding and staging was per-
formed. Intraoperatively, there was a large 30 × 30 × 12
cm friable mass with necrosis and hemorrhagic areas aris-
ing from the mesentery of the transverse colon, with
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tumor deposits were present all over the pelvic perito-
neum. A solid right adnexal mass, 10 × 4 cm was also
present. Resection of tumor with wide margin along with
panhysterectomy and infracolic omentectomy was done.
Cut section of uterus, with bilateral fallopian tubes and
ovaries showed serosal deposits. Endocervix revealed a 4.5
× 4 × 1 cm cauliflower like, exophytic, polypoidal vascular
friable growth lying at the lower end. Vagina was grossly
looking normal. Histopathological examination revealed
a primary gastrointestinal tumor of mesentery with >5
mitoses per 50 high power field and atypical spindle cells
arranged in fascicles. There were metastasis in the cervix,
serosa and omentum. Immunohistochemical stains
showed positivity for vimentin, smooth muscle actin,
desmin and CD 117 (Figure 1) and were negative for
cytokeratin, epithelial membrane antigen and CD 34.
Molecular genetic analysis (KIT mutation analysis) was
not done due to its unavailability at our institute. Postop-
eratively, she received 6 units of packed RBC, fresh frozen
plasma and platelet rich plasma each. She had a stormy
postoperative period with fever, severe pain abdomen and
developed a recurrence after 4 weeks with huge mass per
abdomen and faecal fistula from the surgical scar. On
computerized tomography, there was a large heterogene-
ous mass lesion in pelvis with areas of necrosis infiltrating
sigmoid, iliopsoas with encasement of ureters causing
bilateral hydroureteronephrosis. The mass was involving
the iliopsoas muscle on left side and encasing the ureters
bilaterally (Figure 2). Imatinib 400 mg qd was started
which showed a minimal improvement in her clinical
condition. She continued to have a huge pelvic mass with
pain, fever, urinary and bowel symptoms for which palli-
ative care was administered. RECIST (Response Evalua-
tion Criteria in evaluating Solid Tumors) criteria were
applied for response assessment. At 4 weeks, only 16% of
the lesions achieved partial response (PR) by RECIST and
24% increased in size by a mean of 22.5% (progressive
disease, PD).
Discussion
GIST may present anywhere in the gastrointestinal tract,
omentum, or mesentery. The most common sites are the
stomach (60%), small intestine (15%), colon and rectum
(5%), other abdominal organs including mesentery and
omentum (5%) [2]. Usual age of presentation is around
60 years, predominantly seen in Caucasians with little sex
Cervix with metastatic gastrointestinal tumor, showing fascicles of spindle cells positive for CD 117 stain Figure 1
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difference. Pediatric GISTs have also been reported with
predilection for girls. They have a multicentric distribu-
tion with a high risk of local recurrence and regional
lymph node metastasis, show a predominantly epitheloid
morphology and lack KIT mutations [3]. Patients with
GIST usually present with abdominal mass, gastrointesti-
nal haemorrhage, pain, nausea, and vomiting and/or
weight loss. Our patient had an unusual clinical presenta-
tion of menorrhagia and passage of tissue per vaginum.
The tumor is thought to arise from the interstitial cells of
Cajal. On microscopy, 70% of GISTs are spindle cell
tumors. Nearly all are immunohistologically positive to
CD117 (KIT tyrosine kinase) as in our case, which differ-
entiates it from true leiomyomas, neurofibroma, leiomy-
osarcoma and schwannoma [4]. A diagnosis of GIST was
made in our patient on the basis of histological character-
istics of the tumor, clinical presentation and immunohis-
tochemical profile, including a positive test for the CD117
marker. Most of the GISTs result from a somatic mutation
although rarely familial cases are reported. A KIT activat-
ing mutation occurs in 70 – 80%. There are settings, when
mutation analysis might help with decision making and
the decision for neoadjuvant treatment becomes easier
when exon 11 mutation would be present than no muta-
tion at all. Primary treatment is surgical resection of the
tumor. Induction treatment with imatinib (neoadjuvant
chemotherapy) should be considered before major radical
surgery, if histology can be obtained before as possibly
mutilitating surgical procedures can be avoided. Given the
high probability of response, it may also be considered in
unresectable or inoperable metastasis as it improves the
surgical operability and morbidity and successfully
reduces tumor size in GISTs [5].
This is usually followed by relapse in more than 50% of
patients, which is mostly intraabdominal. Targeted adju-
vant therapy against KIT tyrosine kinase using imatinib
mesylate (ST1571) 400 mg has revolutionized the treat-
ment of GISTs [6]. GISTs have been the lead example, that
classical response criteria are insufficient to measure "clin-
ical success." All large trials have shown that NC and PR
responses show equally good response durations and no
significant difference in the effect on overall survival. This
had a huge impact on many trials, not only GIST, to use
progression free survival as a primary endpoint, instead of
response. GIST may lose KIT expression after imatinib
treatment and require a thorough examination of the
parts of the resected specimen. Some centres perform
CT scan showing the tumor extensions Figure 2
CT scan showing the tumor extensions.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
World Journal of Surgical Oncology 2007, 5:137 http://www.wjso.com/content/5/1/137
Page 4 of 4
(page number not for citation purposes)
monthly CT for response assessment until tumor progres-
sion. Sometimes, false positive complete response (CR) is
noted on PET CT. Parameters recorded are largest dimen-
sion, new lesions, and any new features and tumor
response is assessed through RECIST criteria [7]. They are
a new set of tumor response criteria adopted by WHO, the
National Cancer Institute and the European Organisation
for Research and Treatment of Cancer. To our knowledge,
this is the first case report of mesenteric GIST with metas-
tasis to the uterine cervix in literature. GIST may also
present as a pelvic mass [8] or metastasize to the ovary [9-
11].
Conclusion
Surgery remains the mainstay of known curative treat-
ment. Recently, the diagnosis and management of GIST
has undergone a revolution with the emergence of CD117
staining and the transforming oncogene (KIT mutation).
Its specific targeted inhibition is greatly effective in treat-
ing GIST. The manifestations of GIST are not restricted to
the typical locations within the bowel; may have very unu-
sual metastatic sites or infiltrations per continuitatem.
Thus, a multidisciplinary approach including a gynecolo-
gist and a medical oncologist can improve the prognosis
of patients with GIST.
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